SynthesisFrontiers in immunology2026
Effects of donor killer-cell immunoglobulin-like receptor genotypes on clinical outcome after allogeneic hematopoietic stem cell transplantation-a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purposed: Natural Killer cell kinetics and Killer-cell immunoglobulin-like receptors (KIRs) are increasingly recognized for their role during allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the prognostic impact of donor KIR haplotype configurations on patient survival remains controversial. To clarify this relationship, we conducted a systematic review and meta-analysis evaluating the impact of donor KIR haplotypes on the survival of patients undergoing allo-HSCT. Methods: We systematically searched PubMed, Embase, the Cochrane Library, and CBM. Data were analyzed using RevMan5.4. Pooled hazard ratio (HR) for time-to-event data. Subgroup analyses were performed for sample size, area, donor type, T cell replete or deplete, GVHD prophylaxis, and lymphoid or myeloid. Results: 17 eligible studies were included, and meta-analysis showed that donor KIR B/X genotype is associated with significantly superior overall survival (HR = 0.68, 95%CI, 0.56-0.82; P<0.0001), reduced relapse incidence (HR = 0.61, 95%CI, 0.44-0.85; P = 0.003), and improved relapse-free survival (HR = 0.61, 95%CI, 0.46-0.81; P = 0.0008). Discussion: The findings suggest that donor KIR B/X haplotype is associated with favorable survival outcomes in allo-HSCT including HLA-matched sibling, unrelated donor, and haploidentical transplantation, supporting its potential utility as a reference biomarker for donor selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.